<DOC>
	<DOCNO>NCT01668654</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety tolerability retigabine/ezogabine adjunctive treatment subject either partial onset seizure ( 12 &lt; 18 year old ) Lennox-Gastaut Syndrome ( 12 &lt; 30 year old ) participate previous ( `` parent '' ) study .</brief_summary>
	<brief_title>Long-term , Open-label Safety Extension Study Retigabine/Ezogabine Pediatric Subjects ( &gt; = 12 Years Old ) With POS LGS</brief_title>
	<detailed_description>Epilepsy among common serious neurologic disorder childhood . Medicines novel action mechanisms action need try address unmet clinical need seizure control patient treatment-resistant epilepsy . The purpose study evaluate long-term safety tolerability retigabine/ezogabine adjunctive treatment subject either partial onset seizure ( 12 &lt; 18 year old ) Lennox-Gastaut Syndrome ( 12 &lt; 30 year old ) participate previous ( `` parent '' ) study .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Lennox Gastaut Syndrome</mesh_term>
	<mesh_term>Ezogabine</mesh_term>
	<criteria>Has participate either Phase II Phase III retigabine/ezogabine clinical trial evaluate partial onset seizure seizures comprise LennoxGastaut syndrome meet requirement define parent study transition openlabel extension study Investigator caregiver consider beneficial patient continue treatment retigabine/ezogabine Female subject childbearing potential ( menarche ) must either sexually active must practice acceptable method contraception ( documented medical chart ) two week prior administration study medication 28 day completion premature discontinuation study Subject live his/her custodial parent ( ) legal guardian ( ) contact daily basis Written inform consent obtain subject parent/guardian accompany assent subject . The subject , and/or his/her custodial parent ( ) legal guardian ( ) ability comprehend key component inform consent form Has insufficient ability articulate presence absence urinary tract symptom Has experience adverse event , clinically significant laboratory abnormality discontinue parent study due reason investigator 's judgment would preclude enrollment study Has urine sample : Urine specific gravity &gt; 1.035 , Urine pH &lt; 4.6 &gt; 8.0 , ≥2+ proteinuria , Casts crystal ( type ) , &gt; 5 RBC/HPF , unrelated menses Has blood sample : BUN &gt; 21 mg/dl 12 year old , &gt; 25 mg/dl &gt; 12 year old , Creatinine &gt; 1.03 mg/dl ( F ) , &gt; 1.3 mg/dl ( M ) , Uric acid &gt; 7.5 mg/dl ( F ) , &gt; 8.5 mg/dl ( M ) , Chloride &gt; 108 mEq/L , parameter calcium , inorganic phosphorous CO2 clinically significant judge investigator Has presence clinically significant hepatic laboratory value : aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2x upper limit normal ( ULN ) ; alkaline phosphatase bilirubin ≥1.5xULN ( isolated bilirubin &gt; 1.5ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % Has presence clinically significant cardiac arrhythmia Has abnormality 12lead ECG clinically significant opinion investigator , correct QT interval ( use either Bazett 's Fridericia 's ) &gt; 500msec ( &gt; 530 msec subject Bundle Branch Block ) , uncorrected QT interval &gt; 600msec , change baseline QTc &gt; 60msec Has history one renal calculus Has disturbances micturition know urinary obstruction , include renal calculus Has document anatomical stricture anatomical abnormality urinary tract system potential interfere urinary flow Has experience clinically significant urinary retention and/or require urinary catheterization precede 6 month Has experience 2 objectively documented urinary tract infection precede 12 month Has history inadequate fluid intake clinically significant dehydration precede 6 month Within precede month , take anticholinergic medication ongoing basis Has active suicidal plan/intent active suicidal thought past 6 month history suicide attempt last 2 year one lifetime suicide attempt Is plan surgery implantation vagus nerve stimulator control seizures study Is currently abuse substance ( ) medication 12 month prior study entry Has take investigational drug ( exception retigabine/ezogabine ) , use investigational device , within previous 30 day prior , plan take investigational drug anytime study Females lactate pregnant Unwillingness inability follow procedure outline protocol The subject felt , investigator , unsuitable inclusion study Children care</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>29 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>Partial Onset epilepsy</keyword>
	<keyword>Lennox-Gastaut Syndrome</keyword>
	<keyword>Open-label extension study</keyword>
</DOC>